J. Feng

发表

Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial

Zhihao Lu, Yanqiao Zhang, Q. Fan, 2022, Innovation (Cambridge (Mass.)).

Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Doubleâ•’Blinded, Placeboâ•’Controlled, Randomized Phase III Trial (ALTER0703)

Ying Cheng, He-long Zhang, Y. Shu, 2021 .

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).

Yi-long Wu, Q. Xiu, Chengping Hu, 2012 .

LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.

Yi-long Wu, Wei Li, Chengping Hu, 2013 .

Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.

Ying Cheng, Dong Wang, Yuankai Shi, 2020 .

A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb

Yang Wu, Jian-zhong Wu, Rong Ma, 2021, Cancer Gene Therapy.

Safety, Clinical Activity, and Pharmacokinetics of Al ﬂ utinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation

D. Zhong, N. Yang, S. Qin, 2020 .

Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study

Ming Yan, Yongmei Yin, Bing-he Xu, 2022, Breast Cancer Research and Treatment.

Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)

Yang Zhang, Changli Wang, Wen-Wei Hu, 2022, Cancer communications.

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status

Wei Li, C. Bai, Wei Li, 2017, Scientific Reports.

Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

Wei Li, R. Feng, Yongping Song, 2016, BMC Cancer.

MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study

Ying Cheng, N. Liao, R. Hegg, 2020, Therapeutic advances in medical oncology.

Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced gastric adenocarcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study.

Y. Ba, Fenghua Wang, Yunpeng Liu, 2018 .

Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced esophageal squamous cell carcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study.

Y. Ba, Fenghua Wang, Wei Li, 2018 .

Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC).

Ying Cheng, Yi-long Wu, B. Han, 2019, Journal of Clinical Oncology.

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.

Ying Cheng, Yongmei Yin, Bing-he Xu, 2020 .

Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced nonsquamous NSCLC with wild‐type EGFR and ALK.

Yi Na Wang, Ying Cheng, Jianxing He, 2019, Journal of Clinical Oncology.

An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer.

Bing-he Xu, Qingyuan Zhang, Jiayu Wang, 2018 .

Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial.

Jie He, P. Lu, Y. Ba, 2019, Journal of Clinical Oncology.

Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study).

Bing-he Xu, Huiping Li, Q. Sun, 2023, European journal of cancer.

HKDC1 Silencing Inhibits Proliferation and Glycolysis of Gastric Cancer Cells

Jianqun Lu, Li Jin, J. Feng, 2023, Journal of oncology.

Afatinib in the treatment of advanced NSCLC with EGFR mutation: An observational real-world study.

Y. Kou*, Xiaohua Wang, Yiqun Tang, 2019, Journal of Clinical Oncology.

LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations.

Yi-long Wu, Wei Li, Chengping Hu, 2013 .

Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy.

J. Strausz, S. Ou, Keunchil Park, 2012 .

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study

Yongmei Yin, Bing-he Xu, Huiping Li, 2022, Breast Cancer Research and Treatment.

Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials

Cheng-Ta Yang, Y. Wu, C. Zhou, 2019, Annals of Oncology.

Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).

E. Smit, E. Felip, M. Reck, 2014 .

First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).

B. Han, He-long Zhang, Yunpeng Liu, 2016 .

Clinical practice guidelines on cancer-related anemia (2012-2013 Edition).

Li Zhang, Xuelin Ma, Yuankai Shi, 2012, Chinese clinical oncology.

Abstract GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer

Ming Yan, Ying Cheng, Yongmei Yin, 2022, Cancer Research.

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

Y. Luo, Q. Xiu, Yan Zhang, 2013, Annals of Oncology.

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

Y. Jiang, Y. Ba, R. Xu, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

Ming Yan, Lisong Yang, Bing-he Xu, 2023, Acta pharmaceutica Sinica. B.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Y. Luo, Q. Xiu, Shucai Zhang, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

P79.02 Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC

X. Jiang, J. Fang, F. Wu, 2021 .

OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

X. Jiang, J. Fang, C. Zhu, 2019, Journal of Thoracic Oncology.